Liraglutide is an active pharmaceutical ingredient (API) for the treatment of obesity and type 2 diabetes. As a GLP-1 (glucagon-like peptide-1) receptor agonist, Liraglutide regulates blood sugar and body weight by mimicking the effects of GLP-1. It can enhance insulin secretion, reduce glucose production, suppress appetite, and delay gastric emptying, thereby achieving effective blood sugar control and weight management.

In obesity treatment, Liraglutide helps patients achieve and maintain weight loss by reducing food intake and increasing satiety. In diabetes management, it not only helps to lower fasting blood sugar and postprandial blood sugar, but also improves insulin sensitivity and reduces the risk of diabetic complications.

As a raw material drug, Liraglutide is widely used in a variety of pharmaceutical preparations, helping countless patients improve their health and quality of life. Its clinical studies and applications have shown that the safety and effectiveness of Liraglutide in long-term use make it an important tool in the field of obesity and diabetes treatment.